Table 1 Demographics of patients with locally advanced pancreatic cancer received gemcitabine-based neoadjuvant therapy (GBNAT) and surgical resection
Characteristics | Number of patients, n = 41 |
|---|---|
Sex (M:F) | 27:14 |
Age (years), mean (range) | 63.5 (39–80) |
Location: Head: body: tail | 17:18: 6 |
Naïve: failed exploration | 32:9 |
Chemotherapy(CT)#: chemoradiation therapy (CRT)* | 25:16 |
Response rate | 21 (51.2%) |
CR: PR | 2:19 |
Surgery: non-surgery | 20:21 |
Successful resection | 17 (41.5%) |
Surgical procedure | |
Whipple: central pancreatectomy: distal pancreatectomy | 6: 5: 6 |
Surgical margin | |
R0: R1: R2 | 14: 2:1 |
Pre-GBNAT tumor marker level | |
CEA | 24.9 ± 28.6 |
CA199 | 1641 ± 3697 |
CA125 | 51.1 ± 51.9 |
Post-GBNAT tumor marker level | |
CEA | 20.3 ± 51.2 |
CA199 | 1820 ± 4780 |
CA125 | 82.3 ± 135.5 |
Progression-free survival, median (mean ± SD), months | 9.0 (18.4 ± 3.0) |
Surgery vs non-surgery | 15.0 (32.1 ± 6.0) vs 4.0 (6.7 ± 2.0) |
Overall survival, median (mean ± SD), months | 12.5 (20.8 ± 4.0) |
Surgery vs non-surgery | 21.0 (33.1 ± 7.0) vs 9.0 (10.5 ± 2.0) |